Uncategorized

Regeneron to challenge Ipsen as FDA clears bone disease drug

Published

on

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version